Charles Schwab Investment Management Inc. Has $5.37 Million Stake in AnaptysBio, Inc. (NASDAQ:ANAB)

Charles Schwab Investment Management Inc. grew its position in shares of AnaptysBio, Inc. (NASDAQ:ANAB) by 3.2% in the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 160,321 shares of the biotechnology company’s stock after buying an additional 5,043 shares during the quarter. Charles Schwab Investment Management Inc. owned approximately 0.53% of AnaptysBio worth $5,371,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in ANAB. Ensign Peak Advisors Inc boosted its stake in AnaptysBio by 74.4% in the second quarter. Ensign Peak Advisors Inc now owns 75,755 shares of the biotechnology company’s stock worth $1,898,000 after purchasing an additional 32,313 shares in the last quarter. Victory Capital Management Inc. lifted its stake in AnaptysBio by 677.9% in the third quarter. Victory Capital Management Inc. now owns 237,250 shares of the biotechnology company’s stock valued at $7,948,000 after buying an additional 206,750 shares during the period. Assenagon Asset Management S.A. lifted its stake in AnaptysBio by 55.1% in the third quarter. Assenagon Asset Management S.A. now owns 475,446 shares of the biotechnology company’s stock valued at $15,927,000 after buying an additional 168,813 shares during the period. Alpha DNA Investment Management LLC acquired a new position in AnaptysBio in the second quarter valued at about $399,000. Finally, nVerses Capital LLC lifted its stake in AnaptysBio by 700.0% in the third quarter. nVerses Capital LLC now owns 1,600 shares of the biotechnology company’s stock valued at $54,000 after buying an additional 1,400 shares during the period.

AnaptysBio Stock Down 3.2 %

ANAB opened at $15.02 on Friday. The business has a 50 day moving average of $25.93 and a 200-day moving average of $29.48. The stock has a market cap of $457.04 million, a price-to-earnings ratio of -2.47 and a beta of -0.11. AnaptysBio, Inc. has a 12-month low of $14.20 and a 12-month high of $41.31.

AnaptysBio (NASDAQ:ANAB) last released its quarterly earnings results on Tuesday, November 5th. The biotechnology company reported ($1.14) EPS for the quarter, beating the consensus estimate of ($1.72) by $0.58. AnaptysBio had a negative net margin of 289.75% and a negative return on equity of 287.94%. The business had revenue of $30.02 million for the quarter, compared to the consensus estimate of $7.92 million. As a group, analysts expect that AnaptysBio, Inc. will post -6.02 earnings per share for the current year.

Wall Street Analyst Weigh In

Several equities research analysts have issued reports on ANAB shares. BTIG Research downgraded AnaptysBio from a “buy” rating to a “neutral” rating in a report on Monday, December 2nd. Wedbush reiterated an “outperform” rating and set a $40.00 price objective (down from $42.00) on shares of AnaptysBio in a report on Wednesday. HC Wainwright downgraded AnaptysBio from a “buy” rating to a “neutral” rating and decreased their price objective for the stock from $52.00 to $19.00 in a report on Wednesday. Truist Financial increased their price objective on AnaptysBio from $20.00 to $30.00 and gave the stock a “hold” rating in a report on Thursday, August 15th. Finally, JPMorgan Chase & Co. decreased their price objective on AnaptysBio from $75.00 to $66.00 and set an “overweight” rating for the company in a report on Tuesday, November 12th. Four equities research analysts have rated the stock with a hold rating and eight have given a buy rating to the company’s stock. According to MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $45.09.

Insider Transactions at AnaptysBio

In other news, insider Eric J. Loumeau sold 8,720 shares of the stock in a transaction dated Monday, September 16th. The shares were sold at an average price of $39.82, for a total transaction of $347,230.40. Following the transaction, the insider now owns 7,020 shares of the company’s stock, valued at $279,536.40. This represents a 55.40 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, insider Paul F. Lizzul sold 1,500 shares of the stock in a transaction dated Monday, September 23rd. The stock was sold at an average price of $38.67, for a total transaction of $58,005.00. Following the transaction, the insider now directly owns 15,398 shares in the company, valued at $595,440.66. This trade represents a 8.88 % decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 22,440 shares of company stock valued at $892,936. 33.70% of the stock is currently owned by company insiders.

AnaptysBio Company Profile

AnaptysBio, Inc, a clinical-stage biotechnology company, focuses in delivering immunology therapeutics. Its products include Rosnilimab, an IgG1 antibody that targets PD-1+ T cells, resulting in their agonism or depletion, broadly impacting pathogenic drivers of autoimmune and inflammatory diseases; and ANB032, a non-depleting antibody that binds to the BTLA checkpoint receptor and inhibits activated T cell proliferation; ANB033, a novel anti-CD122 antagonist antibody that targets the shared common beta subunit of the receptors for IL-15 and IL-2; ANB101, a BDCA2 modulator antibody that specifically targets plasmacytoid dendritic cells (pDCs); and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis.